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Abstract 
Background: The gain-of-function mutation JAK2V617F is frequently found in Philadelphia-chromosome-negative 
myeloproliferative neoplasm (MPN) patients. However, the tumorigenic properties of JAK2V617F have mostly been 
characterized in in vivo and in vitro murine models due to the lack of appropriate human cell lines.
Methods: Using the multipotent hematologic cell line UT-7/GM, we established D9, a novel human cell line 
that expresses JAK2V617F upon tetracycline addition. We assessed cellular differentiation in UT-7/GM cells when 
JAK2V617F was induced, and we used microarrays to analyze changes in mRNA expression caused by JAK2V617F.
Results: Using the human D9 cell line, we demonstrated that the induction of JAK2V617F leads to cytokine-
independent cell growth with increased STAT activation and erythroid differentiation, mimicking the characteristics 
observed in polycythemia vera, making it a suitable in vitro model for studying this disorder. Interestingly, JAK2V617F-
dependent erythroid cell differentiation was blocked when GM-CSF was added to the culture, suggesting that the 
GM-CSF pathway antagonizes JAK2V617F-induced erythroid cell differentiation. Our microarray analysis identified sev-
eral genes involved in inflammasome activation, such as AIM2, IL1B, and CASP1, which were significantly up-regulated 
in JAK2V617F-induced cells.
Conclusions: The observed inflammasome activation following JAK2V617F induction is consistent with a recent 
report demonstrating the involvement of IL1B in myelofibrosis development in a JAK2V617F model mouse. These 
results indicate that the D9 cell line should be useful for characterizing the signaling pathways downstream of 
JAK2V617F, allowing for the identification of effector molecules that contribute to the development of MPN.
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Background
Philadelphia-chromosome-negative myeloproliferative 
neoplasms (MPNs) include a range of clonal hematologi-
cal malignant diseases such as polycythemia vera (PV), 
essential thrombocythemia (ET), primary myelofibrosis 
(PMF), and chronic neutrophilic leukemia (CNL). Unlike 
CNL that is associated with CSF3R mutation [1–3], 
PV, ET, and PMF share a common acquired mutation, 
JAK2V617F, which is found in approximately 95 % of PV 
patients and 50  % of ET and PMF patients [4–7]. This 
mutation somatically acquired in myeloid progenitor or 
hematopoietic stem cells [8] plays a causal role in MPN 
development in vivo (reviewed in [9]) and is thus defined 
as a driver mutation.
As opposed to wild-type JAK2, which is only acti-
vated when recruited to cytokine-bound cytokine recep-
tors, JAK2V617F is constitutively activated through 
binding to the cytokine receptor, even in the absence 
of cytokines. JAK2V617F activation stimulates several 
downstream signaling networks, including the STAT3, 
STAT5, ERK/MAP kinase, and PI3 kinase/Akt pathways, 
leading to cytokine-independent cell growth (reviewed 
in [10]). Although activation of these pathways can par-
tially explain the phenotypes observed in MPN patient 
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cells, such as hypersensitivity to erythropoietin (EPO), it 
remains unclear how a single mutation can cause three 
distinct clinical phenotypes in humans [11].
Although human cell lines with the JAK2V617F muta-
tion have been established from patients who had leu-
kemic transformation from ET [12] or erythroleukemia 
[13], the use of these cell lines to study JAK2V617F func-
tion is limited by the leukemic transformation and con-
comitant loss of cytokine responsiveness. Therefore, 
studies of this mutation have been largely carried out 
using murine cell lines, and no other human cell lines 
carrying JAK2V617F have since been established. In 
this study, we established a novel human cell line with 
inducible JAK2V617F expression to determine how this 
mutation affects the regulation of other genes/networks 
downstream of JAK2. We used UT-7/GM as the basis for 
the cell line, which has the unique ability to differentiate 
into erythrocytes or megakaryocytes, depending on the 
presence of EPO or thrombopoietin (TPO), respectively 
[14, 15]. These cells will be an invaluable tool with which 
to investigate the downstream effectors of JAK2V617F, 
which should allow us to elucidate the relationship 
between MPNs and the JAK2V617F mutation.
Methods
Plasmid construction
A 3.4 kb JAK2 cDNA with a G2490A substitution caus-
ing the V617F mutation was amplified by PCR and 
subcloned using TOPO-cloning into pcDNA3.1D (Inv-
itrogen, Carlsbad, CA, USA). Using PCR and subse-
quent subcloning, the stop codon in the JAK2 cDNA 
was deleted, resulting in the addition of a V5-tag with a 
spacer sequence (derived from the vector) at the carboxy-
terminal of JAK2. The V5-tagged JAK2V617F cDNA was 
excised using PmeI and SacI digestion, blunted, and then 
inserted into the PmeI site of pcDNA4/TO (Invitrogen) 
to generate the final Tet-inducible construct (Fig. 1a).
Establishment of a Tet‑inducible cell line
The parental cell line UT-7/GM/TetR, which constitu-
tively expresses the Tet-repressor (TetR) [16], was cul-
tured in Iscove’s Modified Dulbecco’s Media (IMDM) 
supplemented with 10  ng/ml GM-CSF, 10  % (v/v) heat-
inactivated Tet-free fetal bovine serum (FBS) (Takara Bio 
Company, Otsu, Japan), and penicillin–streptomycin at 
37 °C in a 5 % CO2 incubator.
The construct carrying the JAK2V617F gene was 
introduced into UT-7/GM/TetR cells using Amaxa® 
Nucleofector (Lonza, Basel, Switzerland) based on the 
protocol for nucleofection of suspension cell lines. The 
transfected cells were cultured for 48 h in 100 mm petri 
dishes, and then distributed into 24-well plates contain-
ing fresh medium with 200  µg/ml zeocin (Invitrogen) 
to select cells. Resistant cells in each well were inde-
pendently transferred into 6-well plates to screen for 
cells that induced JAK2V617F. The cells were cultured 
with or without Tet (1 µg/ml) (Sigma-Aldrich, St. Louis, 
MO, USA) for 24  h before harvesting to prepare whole 
cell lysates for immunoblotting analysis. Positive clones 
that showed Tet-inducible JAK2V617F expression were 
selected and used to create single-cell colonies in methyl-
cellulose-based medium. Individual colonies were picked 
and cultured for another round of immunoblotting 
screening for Tet-dependent induction. Positive clones 
were then stored at −80 °C. Cell proliferation and viabil-
ity (Fig. 2a, b) were determined using the trypan-blue dye 
exclusion assay with a TC10 Automated Cell Counter 
(Bio-Rad, Hercules, CA, USA).
Immunoblotting analysis
To prepare cell extracts for immunoblotting analy-
sis, cells were washed twice with PBS containing 1 mM 
orthovanadate and then lysed with lysis buffer Cel-
Lytic M (Sigma-Aldrich) supplemented with a protease 
and phosphatase inhibitor cocktail (Thermo Scien-
tific, Waltham, MA, USA, Cat#78440) under vigorous 
shaking on ice for 30  min. Protein concentration was 
determined using a BCA Protein Assay Kit (Thermo 
Scientific). Equal amounts of protein were denatured, 
electrophoresed, and transferred to a PVDF membrane 
(Millipore, Billerica, MA, USA). For detection, a mouse 
monoclonal anti-V5 antibody (Life Technologies, Carls-
bad, CA, USA) was used. Other antibodies used to detect 
related signals included phospho-JAK2 (Tyr1007/1008) 
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Fig. 1 Creation of the Tet-inducible JAK2V617F-expressing cell line 
D9. a A schematic representation of the Tet-inducible construct 
containing the JAK2V617F gene tagged with a V5 epitope. b Confir-
mation of JAK2V617F induction. Equal amounts of protein prepared 
from clones treated with Tet or vehicle alone for 24 h were subjected 
to immunoblotting analysis using an anti V5 antibody to detect 
JAK2V617F
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(CST#3771), phospho-STAT1 (CST#9171), phospho-
STAT3 (CST#9145), phospho-STAT5 (CST#9359), JAK2 
(CST#3230), STAT1 (CST#9172), STAT3 (CST#9132), 
and STAT5 (CST#9363), which were purchased from Cell 
Signaling Technology (Danvers, MA, USA). The horse-
radish peroxidase-conjugated secondary antibodies used 
were a polyclonal rabbit anti-mouse IgG (DAKO, Santa 
Clara, CA, USA, #Z0259) for the mouse monoclonal 
anti-V5 antibody and a goat anti-rabbit IgG (Santa Cruz, 
Dallas, TX, USA, #sc-2004) for other primary antibod-
ies. The chemiluminescence reaction was performed 
using the Pierce ECL Western Blotting Femto reagents 
(Thermo Scientific), and images were captured using 
LAS-3000 or LAS-4000 scanners (Fuji, Tokyo, Japan).
O‑dianisidine staining
D9 cells cultured for a week under various conditions were 
spun down, washed once with PBS, and then resuspended 
with serum-free RPMI. Next, a one-tenth volume of 
freshly prepared O-dianisidine staining solution (18.2 mg/
mL O-Dianisidine/2.7  % hydrogen peroxide/2.7  % ace-
tic acid) was added to each of the cell suspensions, and 
the cell mixtures were incubated at room temperature 
for 30 min. Cells were finally collected on glass slides via 
cytospin, and brown cells were counted by microscopy.
Gene expression profiling and pathway analysis
RNA was isolated with TRIzol Reagent (Invitrogen) and 
purified using the Pure link RNA Mini Kit (Invitrogen) 
based on the manufacturer’s protocol. Microarray sam-
ples were prepared using 3′-IVT Expression Kit (Affym-
etrix, Santa Clara, CA, USA) and hybridized to a U133 
microarray (Affymetrix), according to the manufacturer’s 
instructions. Following RMA normalization, significant 
differentially expressed genes were identified as the over-
lap between lists created using significance analysis of 
microarrays (SAM, q =  0) [17] and the receiver operat-
ing characteristic (ROC, pAUC =  1) [18]. For the path-
way analysis, ssGSEA was applied to compute MSigDB 
v3.0 pathway enrichment scores for the samples [19, 20]. 
Subsequently, SAM/ROC was applied to the enrichment 
scores to identify significantly up-regulated pathways 
(q = 0, pAUC = 1). Up-regulated pathways were further 
evaluated based on information in the KEGG database 
(http://www.genome.jp/kegg/pathway.html).
Quantitative RT-PCR (qRT-PCR) was performed as 
described previously [21]. The qRT-PCR conditions used 
were 95 °C for 1 min, 45 cycles of 95 °C for 15 s, and 60 °C 
for 30  s. The following primers were used for RT-PCR: 
JAK2 (forward: 5′-TCTGGGGAGTATGTTGCAGAA-3′, 
reverse: 5′-AGACATGGTTGGGTGGATACC-3′); and 
AIM2 (forward: 5′-CAGACCCGGTTTGCTGAT-3′, 
reverse: 5′-TTACTCTCCATCTGACAACTTTGG-3′).
Results
Establishment of a JAK2V617F inducible cell line
To study the biological roles of the JAK2V617F oncogene 
product, we established a cell line in which JAK2V617F 
expression can be controlled by the addition of Tet. We 
employed a multipotent hematologic cell line, UT-7/
GM [14, 15], so that we could assess the effects of 
JAK2V617F expression on both cell proliferation and dif-
ferentiation. Using transfection and subsequent random 
insertion into the genome, we introduced a V5-tagged 
version of JAK2V617F cDNA under control of the Tet-
ON promoter (Fig.  1a) into UT-7/GM/Tet-R cells that 
constitutively expressed Tet-R [16]. Cells bearing the 
expression construct were selected by culturing in zeo-
cine-containing media, cloned from individual colonies 
in methylcellulose media, and then further screened for 
Tet-dependent induction of V5-tagged JAK2V617F using 
immunoblotting analysis. We isolated three independ-
ent clones: B1, B8, and D9. As D9 showed the strongest 
JAK2V617F induction following Tet addition (Fig.  1b), 
we employed this clone in subsequent analyses.
Cytokine‑independent cell growth of the D9 cell line 
with STAT activation
As JAK2V617F can activate the JAK-STAT pathway in 
the absence of cytokines in the murine pro-B cell line, 
resulting in cytokine-independent cell growth [22, 23], 
we asked whether the same phenomenon occurred in 
D9 cells. We cultured D9 cells in the absence of GM-
CSF, an essential cytokine for the parental UT-7/GM 
cell line, with or without Tet addition for JAK2V617F 
induction. As shown in Fig.  2a, in the presence of Tet, 
D9 cells grew normally despite the absence of GM-CSF, 
whereas cell proliferation was strongly suppressed in the 
absence of Tet or GM-CSF. The viability of cells remained 
high for 5  days in Tet- or GM-CSF-supplemented cul-
ture, whereas removal of both factors resulted in signifi-
cant reductions in cell viability (Fig.  2b). These findings 
demonstrate that the D9 cell line promotes cytokine-
independent cell proliferation due to the Tet-induced 
expression of JAK2V617F.
To investigate whether JAK2V617F induction activates 
the JAK-STAT pathway in D9 cells, we examined the 
phosphorylation status of three important downstream 
molecules of JAK signaling: STAT1, STAT3, and STAT5. 
D9 cell extracts were prepared at different time points 
after Tet addition and subjected to immunoblotting anal-
ysis. In response to JAK2V617F induction (which reached 
maximum levels 24  h after Tet addition), we observed 
increased phosphorylation for STAT1, 3, and 5, as well as 
JAK2 in D9 (Fig. 2c) but not in parental UT-7/GM/TetR 
cells (Additional file 1: Figure S1). This evidence suggests 
that D9 cells acquire cytokine-independent cell growth 






















































Fig. 2 Cytokine-independent growth of D9 cells through JAK2 and STAT-activation. a A cell growth curve for D9 cells cultured in the presence of 
GM-CSF (GM, triangle) or Tet (circle) supplemented every other day, or in the absence of both GM-CSF and Tet (square). Cell numbers were counted 
daily for the indicated period, and growth relative to day 1 for each condition is shown. b At the same time, cell viability was also assessed using 
a dye exclusion assay, and representative samples are shown. c JAK2 and STAT activation upon JAK2V617F induction. Equal amounts of protein 
from cells treated with Tet for the indicated periods were analyzed by immunoblotting analysis with the indicated antibodies. Note that the level of 
JAK2V617F and phosphor-STATs were decreased in 48 and 72 h compared to 24 h due to degradation of Tet, which was only added in the media at 
time 0
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at least in part, if not all, through activation of the JAK-
STAT signaling pathway.
JAK2V617F induction promotes erythroid cell 
differentiation in D9 cells
Next, we examined whether JAK2V617F induction affects 
cell lineage determination in D9 cells, as the parental cell 
line is multipotent [15]. D9 cells were cultured under 
four different conditions: (1) Tet, (2) Tet and GM-CSF, 
(3) GM-CSF, and (4) EPO. After a week of culturing, 
cells were subjected to O-dianisidine staining (Methods) 
(Fig.  3a); stained and unstained cells were counted, and 
the results were plotted on a bar graph (Fig.  3b). Cells 
expressing JAK2V617F under the control of Tet differen-
tiated to erythroid cells at levels similar to what was seen 
in the EPO-treated cells (Fig. 3). By contrast, in the pres-
ence of GM-CSF, cells remained undifferentiated, even in 
the presence of Tet. These data suggest that JAK2V617F 
induction itself promotes erythroid differentiation and 
that JAK2V617F-dependent differentiation is blocked 
by GM-CSF. The EPO-independent cell growth and the 
induction of erythroid differentiation by JAK2V617F in 
the D9 cell line suggests that this cell line has the same 
characteristics of PV following induction, making it suit-
able for use as an in vitro model to study PV.
Identification of AIM2 as a downstream target 
of JAK2V617F
To investigate the transcriptional cascade downstream 
of JAK2V617F, we performed a microarray-based 
mRNA expression analysis followed by single-sample 
gene set enrichment analysis (ssGSEA). Total RNA and 
cell lysates were prepared from D9 or UT-7/GM/TetR 
(control) cells that were subjected to a 3-h starvation 
period without GM-CSF, and then cultured in the pres-
ence of Tet for 0 (control), 6, or 24  h. The induction of 
JAK2V617F expression was confirmed by qRT-PCR and 
immunoblotting analysis (Fig.  4a). Then, RNA samples 
obtained from three independent experiments were sub-
jected to microarray analysis. The pathway enrichment 
scores computed by ssGSEA based on SAM/ROC were 
compared between the D9 datasets at 6 and 24 h of Tet 
induction (JAK2V617F-induced D9) and the datasets 
for UT-7/GM/TetR (all time points) and D9 with no 
Tet induction (control). Among the 21 KEGG pathways 
that were classified as up-regulated in D9 cells (data not 
shown), we identified a cytosolic DNA sensing pathway 
that is involved in inflammasome activation. In particu-
lar, the genes associated with inflammasome activation, 
such as AIM2, CASP1, and IL1B, were strongly induced 
by JAK2V617F induction (Fig. 4b).
In clinical, PMF patients present increased level of pro-
inflammatory cytokines such as IL1B [24]. Because AIM2 
is reported to play an important role in IL-1B regulation 
[25, 26] and significantly induced in our assay (Fig.  4b), 
we further confirmed the up-regulation of AIM2 by 
JAK2V617F using qRT-PCR. As shown in Fig.  4c, we 
observed a nearly fourfold increase in AIM2 gene expres-
sion at 24 h of Tet induction relative to the 0 h (control). 
Therefore, we concluded that AIM2 is a downstream tar-
get of JAK2V617F in D9 cells.
Discussion
In the present study, we describe the creation of a cell 
line, D9, which contains a tetracycline-inducible form 
of the JAK2V617F cDNA and was based on a sub-
line of the acute megakaryoblastic leukemia UT-7 cell 
































Fig. 3 Induction of erythroid differentiation by JAK2V617F expres-
sion. a Images of O-dianisidine-stained D9 cells cultured under 
the indicated conditions for 7 days. b Bar graph representing the 
percentage of cells stained by O-dianisidine in each of the indicated 
conditions
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phosphorylation of downstream effector proteins such 
as STAT1, STAT3, and STAT5, leading to GM-CSF-
independent growth and the induction of erythroid dif-
ferentiation. Using a microarray analysis and ssGSEA, we 
identified a group of genes in the inflammasome path-
way that were significantly up-regulated in JAK2V617F-
induced cells. The robust induction of AIM2, a key 
component of the pathway, was confirmed by qRT-PCR, 
suggesting that AIM2 may be a downstream effector of 
JAK2V617F and may play a role in the development of 
myelofibrosis (discussed below).
Consistent with previous reports in a murine cell line 
[22, 23], the expression of JAK2V617F promotes STAT 


















































Fig. 4 Identification of AIM2 as a downstream target of JAK2V617F. a Presumptive JAK2V617F induction was verified by qRT-PCR analysis for JAK2 at 
the indicated time points after Tet induction, as shown in the lower panel. V5-tagged JAK2V617F induction was observed by immunoblotting analy-
sis (upper panel). Note that qRT-PCR did not discriminate between endogenous JAK2 and Tet-induced V5-tagged JAK2V617F mRNA, thus the rate of 
JA2V617F mRNA induction may be underrepresented. b A heat map showing the expression of genes in the cytosolic DNA sensing pathway in D9 
and UT-7/GM/TetR (control) cells at the indicated time points. RNA samples from three independent experiments were analyzed. Green indicates 
lower gene expression and red indicates higher gene expression. c qRT-PCR analysis of AIM2 expression using the cDNA analyzed in (b). d A model 
explaining the potential roles of how AIM2 and IL1B might act downstream of JAK2V617F to contribute to myelofibrosis
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in human leukemia UT-7/GM cells (Fig.  2). Although 
some leaky expression of JAK2V617F (in the absence 
of Tet) was detected by our immunoblotting analyses 
(Figs.  1b, 2c, 4a), that level of JAK2V617F was not suf-
ficient to generate GM-CSF-independent D9 cells, pre-
sumably due to the counteracting effects of the two 
copies of wild-type JAK2 [27] against the relatively weak 
JAK2V617F [28].
The UT-7/GM cell line is capable of differentiating into 
megakaryocytic and erythroid lineage cells in response 
to TPO and EPO, respectively. In D9 cells, however, 
the induction of JAK2V617F in the absence of GM-CSF 
results in differentiation towards the erythroid lineage 
(Fig. 3). This phenomenon is likely due to the high levels 
of JAK2V617F, as increased JAK2V617F allele frequen-
cies and expression levels have been linked to cellular 
differentiation towards erythroid lineages in both MPN 
patients and murine models [9, 29, 30]. However, we note 
that UT-7/GM cells respond quicker to EPO compared 
with TPO, as judged by EPO receptor (EPOR) and TPO 
receptor (c-MPL) expression [15], indicating that UT-7/
GM cells are predisposed to differentiate towards an 
erythroid cell lineage.
We observed that GM-CSF blocked the JAK2V617F-
induced erythroid cell differentiation in D9 cells (Fig. 3), 
consistent with our previous finding that GM-CSF coun-
teracts EPO signaling pathway in UT-7/GM cells, the 
parental cell line of D9 [15]. In addition, it was reported 
that JAK2V617F requires cytokine receptor binding for 
the activation of downstream pathway [31]. These obser-
vations suggest that although JAK2V617F is capable of 
transforming cells in a certain context, its function is 
restricted by counteracting signaling cascades related to 
cell linage. Thus, this mutation is predominantly found 
in PV, ET, and PMF patients who exhibit aberrant eryth-
rocytosis and/or megakaryocytosis, but not commonly 
in other myeloproliferative neoplasms such as CNL and 
chronic myeloid leukemia. Further understanding con-
text-dependent oncogenic functions of JAK kinases are 
beneficial for the development of novel therapeutic strat-
egies to overcome issues in the treatment of MPN [32] 
and other hematopoietic malignancies [33]. Neverthe-
less, the JAK2V617F-induced cytokine-independent cell 
proliferation and erythroid differentiation exhibited by 
D9 cells in this study demonstrates the two key features 
of PV, making it a suitable in vitro model for further stud-
ies of the causal role of JAK2V617F.
Using mRNA microarray analysis and subsequent 
ssGSEA, we identified a cytosolic DNA-sensing pathway 
that includes genes involved in formation of the inflam-
masome (Fig. 4). Basal AIM2 expression in non-induced 
D9 cells was significantly higher than in UT-7/GM/TetR 
control cells (Fig.  4c), suggesting that leaky JAK2V617F 
expression is sufficient to induce AIM2 expression, which 
was increased further in Tet-induced D9 cells (Fig.  4c). 
As AIM2 plays a crucial role, along with CASP1, in con-
verting pro-IL1B to its active form [25, 26], the induction 
of the AIM2, CASP1, and IL1B mRNAs in JAK2V617F-
induced cells suggests that IL1B activation is linked to 
MPN development. More recently, IL1B secreted from 
JAK2V617F-positive hematopoietic stem cells has been 
shown to induce inflammation and promote the devel-
opment of myelofibrosis in the bone marrow in ani-
mal models [34]. Our microarray analysis also revealed 
increased levels of DDX58 mRNA, another component of 
the cytosolic DNA sensing pathway (Fig. 4b). DDX58 was 
previously identified as one of the MPN-associated genes 
that exhibits genomic amplification at chromosome 9 in 
MPN patients, compared with normal healthy individu-
als [35]. This suggests that increases in DDX58 gene dos-
age could contribute to MPN pathogenesis. Although 
we successfully identified genes of which expression is 
induced by JAK2V617F in D9 cells, we note that the con-
tinuous leaky expression of JAK2V617F may alter the cel-
lular property and its response to JAK2V617F. Further 
analysis using more defined assay system is required for 
gaining clearer and definitive view on genes regulated by 
JAK2V617F. Finally, we propose a model in which high 
levels of JAK2V617F induce the expression of inflammas-
ome-related genes, triggering myelofibrosis development 
in the bone marrow, which has been associated with 
increased JAK2V617F allele frequencies in patients [4, 
6, 36, 37] and high levels of mutant expression in animal 
models [9] (Fig. 4d).
Conclusions
The induction of JAK2V617F expression in D9 cells 
promoted cell proliferation in the absence of a growth 
cytokine (GM-CSF) and led to erythroid differentia-
tion, making this human cell line-based model useful for 
studying the causal effects of the JAK2V617F mutation 
on MPN development. Using D9 cells, we identified sev-
eral genes involved in the inflammasome pathway, such 
as AIM2, IL1B, and CASP1, as downstream targets of 
JAK2V617F, which could explain the molecular mecha-
nism behind myelofibrosis development in patients 
harboring the JAK2V617F mutation. Further studies to 
elucidate the activities of these downstream signals and 
pathways should shed light on MPN development, which 
could lead to the creation of drugs targeting the effectors 
of the JAK2V617F mutation.
Additional file
Additional file 1: Figure S1. No inductionon of pJAK2 and pSTAT3 in the 
parental UT-7/GM/TetR cells by Tet.
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